{"id":62534,"date":"2024-12-09T12:05:20","date_gmt":"2024-12-09T12:05:20","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/12\/09\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/"},"modified":"2024-12-09T12:05:20","modified_gmt":"2024-12-09T12:05:20","slug":"aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/","title":{"rendered":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer"},"content":{"rendered":"<div>\n<ul>\n<li>AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC)<\/li>\n<\/ul>\n<p align=\"justify\">COSA MESA, Calif., Dec.  09, 2024  (GLOBE NEWSWIRE) &#8212; AiViva Biopharma Inc., a clinical-stage biotechnology company, announced the receipt of FDA clearance for testing AIV001 (axitinib) by intradermal injection with their formulation in facial skin. AIV001 is a pan-tyrosine kinase inhibitor in a proprietary formulation, designed for prolonged drug release. This FDA clearance was supported by AiViva\u2019s submission of safety data on non-facial skin tolerability and efficacy, and systemic exposure from 67 subjects treated with AIV001 in BCC and in scar management.<\/p>\n<p align=\"justify\">\u201cThis agreement allows a clear path forward to develop AIV001 in cosmetically sensitive skin that includes the face, neck, and scalp, and sets it on track to be the first therapeutic developed for facial skin areas having sBCC or nBCC lesions,\u201d said Diane Tang-Liu, PhD, President and CEO of AiViva. \u201cWe are excited about the product prospect of AIV001 using a focal delivery method that is supported by our strong intellectual property position,\u201d continued Diane Tang-Liu.<\/p>\n<p align=\"justify\">To date, AiViva has completed three clinical studies using intradermal injection of AIV001. Subjects received one to three treatments, three weeks apart. The potency of AIV001 and prolonged drug release in the skin provided clinical and histological clearance of biopsied-confirmed BCC lesions in 26 patients. In addition, a total of 41 subjects were treated in two trials using scar models. Reduced fibrosis formation was observed after a single intradermal injection over the surgical incisional wounds and indicated AIV001\u2019s potential use in scar management. \u201cThis was an important achievement for the clinical development of AIV001 allowing us to expand our ability to evaluate AIV001\u2019s utility in dermatological conditions,\u201d concluded Darlene Deecher, AiViva\u2019s Vice President of Clinical Development.<\/p>\n<p align=\"justify\">About AiViva Biopharma, Inc.<\/p>\n<p align=\"justify\">AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. AiViva has developed innovative approaches to address high unmet medical needs by transforming treatment paradigms through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. Core competencies include development of novel drugs using proprietary technologies, including JEL<sup>\u00ae<\/sup>, in specialty therapeutic areas of dermatology, ophthalmology, urology and oncology. AIV001 is an investigational product candidate in clinical development. The efficacy and safety profiles have not been established, and they have not been approved for marketing by the Food and Drug Administration.<\/p>\n<p align=\"justify\">Follow the Company on its website and LinkedIn for updates.<\/p>\n<p align=\"justify\">Investors &amp; Media<\/p>\n<p align=\"justify\">AiViva Biopharma, Inc<\/p>\n<p align=\"justify\">Shane Cerrato<\/p>\n<p align=\"justify\">Vice President, Business Development<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=syXU7BbIlkLPswoucWj4E_JVAGd3kWyny-fPoALafldtVkbe8Y81qjv-07bx3Gifrbw4Zuzn_ejryQFP96Xx3Q==\" rel=\"nofollow\" target=\"_blank\" title=\"Shane@aiviva.com\">Shane@aiviva.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2NhMjhkMTItNzY0NS00ODdmLThhYzYtNmZjNDIwMzNhMTQ3LTEyMTE2Nzg=\/tiny\/AiViva-Biopharma.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; AiViva Biopharma Inc., a clinical-stage biotechnology company, announced the receipt of FDA clearance for testing AIV001 (axitinib) by intradermal injection with their formulation in facial skin. AIV001 is [&#8230;]\n","protected":false},"author":1,"featured_media":62535,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62534","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer\" \/>\n<meta property=\"og:description\" content=\"AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T12:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/12\/AiViva-Biopharma.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer\",\"datePublished\":\"2024-12-09T12:05:20+00:00\",\"dateModified\":\"2024-12-09T12:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\"},\"wordCount\":444,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\",\"name\":\"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-12-09T12:05:20+00:00\",\"dateModified\":\"2024-12-09T12:05:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/","og_locale":"en_US","og_type":"article","og_title":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer","og_description":"AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec.","og_url":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-12-09T12:05:20+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/12\/AiViva-Biopharma.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer","datePublished":"2024-12-09T12:05:20+00:00","dateModified":"2024-12-09T12:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/"},"wordCount":444,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/","url":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/","name":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-12-09T12:05:20+00:00","dateModified":"2024-12-09T12:05:20+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/aiviva-biopharma-receives-fda-clearance-to-administer-aiv001-in-facial-skin-by-intradermal-injection-for-nonmelanoma-skin-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=62534"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/62534\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/62535"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=62534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=62534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=62534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}